Get the Stockscreener App
7.67
2.82%
0.21
After Hours:
7.61
-0.06
-0.78%
Silence Therapeutics Plc Adr stock is traded at $7.67, with a volume of 499.43K.
It is up +2.82% in the last 24 hours and down -57.58% over the past month.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.
See More
Previous Close:
$7.46
Open:
$7.5
24h Volume:
499.43K
Relative Volume:
1.56
Market Cap:
$352.22M
Revenue:
$31.37M
Net Income/Loss:
$-53.77M
P/E Ratio:
-5.3893
EPS:
-1.4232
Net Cash Flow:
$-49.02M
1W Performance:
+10.68%
1M Performance:
-57.58%
6M Performance:
-64.99%
1Y Performance:
-36.45%
1-Day Range:
$7.46
$7.70
1-Week Range:
$6.43
$8.74
52-Week Range:
$5.81
$27.72
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
Name
Silence Therapeutics Plc Adr
Sector
Industry
Phone
-
Address
-
Compare SLN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLN
Silence Therapeutics Plc Adr
|
7.67 | 352.22M | 31.37M | -53.77M | -49.02M | -1.4232 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr Stock (SLN) Latest News
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels - MSN
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study - Yahoo Finance
United States shares mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com
Silence Therapeutics weakness after AHA updates ‘overdone,’ says BMO Capital - TipRanks
SILENCE THERAPEUTICS PLC SPONSORED ADR trading resumes - TipRanks
Top 3 Health Care Stocks You'll Regret Missing In Q4 - Benzinga
Silence Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Silence Therapeutics: Rising Assets Amid Growing Losses - TipRanks
Novartis Gets CHMP Recommendation for Kisqali in Broader Population - Yahoo Finance
80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - 新浪香港
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty - Yahoo Finance
Silence Therapeutics's SWOT analysis: stock poised for growth in genetic medicine By Investing.com - Investing.com South Africa
Silence Therapeutics's SWOT analysis: stock poised for growth in genetic medicine - Investing.com
Biogen's Lupus Candidate Meets Key Goals in Phase III Study - Yahoo Finance
CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease - Yahoo Finance
It makes sense and dollars to buy Silence Therapeutics Plc ADR (SLN) stock - SETE News
Silence Therapeutics Plc ADR (SLN) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
What Did We Find About Insider Trading At Silence Therapeutics Plc ADR (NASDAQ: SLN)? - Stocks Register
Silence Therapeutics shares start at Buy from Jefferies, reflecting strong clinical data - Investing.com UK
H.C. Wainwright reiterates Buy on Silence Therapeutics stock amid strong trial results By Investing.com - Investing.com South Africa
GSK's RSV Vaccine Arexvy Gets EU Nod for Adults Aged 50-59 Years - Yahoo Finance
How did Silence Therapeutics Plc ADR (SLN) fare last session? - US Post News
Ratio Revelations: Silence Therapeutics Plc ADR (SLN)’s Financial Metrics in the Spotlight - The Dwinnex
Silence Therapeutics Plc ADR (SLN) deserves closer scrutiny - US Post News
Market Insight: Silence Therapeutics Plc ADR (SLN)’s Notable Drop, Closing at 16.70 - The Dwinnex
It would be worthwhile to take a closer look at Silence Therapeutics Plc ADR (SLN) - US Post News
Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last? - Yahoo Finance
Silence Therapeutics Plc ADR (SLN) deserves closer scrutiny – US Post News - US Post News
Silence Therapeutics stock holds Buy rating on positive trial results By Investing.com - Investing.com India
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics - Yahoo Lifestyle UK
Hardman & Co Insight: Survival of the UK life sciences sector - Research Tree
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Altria maintains stock target, Buy rating on FDA move By Investing.com - Investing.com UK
Zerlasiran shows promise in phase 2 study for cardiovascular risk By Investing.com - Investing.com
Is Silence Therapeutics Plc ADR (SLN) a good investment opportunity? – US Post News - US Post News
Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates - Yahoo Finance
Trading Day Triumph: Silence Therapeutics Plc ADR (SLN) Ends at 21.54, a -2.49 Surge/Plunge – DWinneX - The Dwinnex
Kirby Corp CEO sells shares worth over $360k By Investing.com - Investing.com
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains? - Yahoo Finance
BMO maintains $67 stock target on Silence Therapeutics stock By Investing.com - Investing.com UK
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look - Seeking Alpha
Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains? - Yahoo Finance
All You Need to Know About Silence Therapeutics PLC Sponsored ADR (SLN) Rating Upgrade to Strong Buy - Yahoo Finance UK
Does Silence Therapeutics PLC Sponsored ADR (SLN) Have the Potential to Rally 187.05% as Wall Street Analysts Expect? - Yahoo Finance
Wall Street Analysts Predict a 361.54% Upside in Silence Therapeutics PLC Sponsored ADR (SLN): Here's What You ... - Yahoo Finance UK
symbol__ Stock Quote Price and Forecast - CNN
BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains? - Yahoo Canada Finance
The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues - Benzinga
The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO - Benzinga
Silence Therapeutics Plc Adr Stock (SLN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):